tbuckley/cabot-search huggingface dataset:
Preparations of Dispersions of Carcinogenic Hydrocarbons and Hormones With the Aid of Dioctyl Ester of Sodium Sulfosuccinate (Aerosol O. T.)
Authors: Egon Lorenz, Michael B. Shimkin, Harold L. Stewart
Journal: JNCI Journal of the National Cancer Institute (1940)

Preparations of Dispersions of Carcinogenic Hydrocarbons and Hormones With the Aid of Dioctyl Ester of Sodium Sulfosuccinate (Aerosol O. T.) Get access Egon Lorenz, Egon Lorenz senior biophysicist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin, Michael B. Shimkin assistant surgeon National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Harold L. Stewart Harold L. Stewart senior pathologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 3, December 1940, Pages 355–360, https://doi.org/10.1093/jnci/1.3.355 Published: 01 December 1940
FRI0586 Interleukin (IL)-1 inhibition with anakinra and canakinumab in behÇet's disease related uveitis: a multicenter retrospective observational study
Authors: C Fabiani, A Vitale, G Emmi, G Lopalco, L Vannozzi, S Guerriero, S Gentileschi, D Bacherini, R Franceschini, B Frediani, M Galeazzi, F Iannone, GM Tosi, L Cantarini
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> To evaluate the role of interleukin (IL)-1 inhibitors anakinra (ANA) and canakinumab (CAN) in the treatment of Behçet disease (BD)-related uveitis <h3>Methods</h3> multicenter retrospective observational study including 19 consecutive BD patients (31 affected eyes) receiving treatment with anti-IL-1 agents. Data were analyzed at baseline, at 3 and 12 months. Primary end-point: reduction of ocular inflammatory flares (OIF). Secondary end-points: improvement of Best Corrected Visual Acuity (BCVA); reduction of macular thickness defined by optical coherence tomography (OCT) and of vasculitis identified with fluorescein angiography (FA); evaluation of statistically significant differences between patients treated with IL-1 inhibitors as monotherapy, subjects also administered with disease modifying anti-rheumatic drugs (DMARDs) and/or corticosteroids as well as between patients administered with IL-1 inhibitors as first line biologic treatment and those previously treated with TNF-α inhibitors <h3>Results</h3> at 12 months OIF significantly decreased from 200/100 patients/year to 48.87/100 patients/year (p&lt;0.0001). The frequency of retinal vasculitis identified by FA significantly decreased between baseline, 3-month and 12-month follow-up visits (<i>p</i>&lt;0.0001 and <i>p</i>=0.001, respectively). OIF rate was significantly higher in patients co-administered with DMARDs (81.8/100 patients/year) than in patients undergoing IL-1 inhibitors as monotherapy (0.0/100 patients/year) (<i>p</i>=0.03). No differences were identified on the basis of corticosteroid use and between patients administered with IL-1 inhibitors as first-line biologic approach or second-line. Steroid dosage was significantly decreased at 12-month visit compared to baseline (<i>p</i>=0.02). <h3>Conclusions</h3> treatment with IL-1 inhibitors is effective in the management of BD-related uveitis and provides a long-term control of ocular inflammation in refractory and long-lasting cases. <h3>Disclosure of Interest</h3> None declared
Optical Coherence Tomography Predictors of Risk for Progression to Non-Neovascular Atrophic Age-Related Macular Degeneration
Authors: Karim Sleiman, Malini Veerappan, Katrina P. Winter, Michelle N. McCall, Glenn Yiu, Sina Farsiu, Emily Y. Chew, Traci Clemons, Cynthia A. Toth, Cynthia A. Toth, Wai Wong, Thomas Huang, G. Baker Hubbard, Sunil Srivastava, Michelle McCall, Katrina Winter, Neeru Sarin, Katherine Hall, Patti McCollum, Linda Curtis, Stefanie Schuman, Stephanie J. Chiu, Sina Farsiu, Vincent Tai, Traci Clemons, Emily Chew
Journal: Ophthalmology (2017)
The development of a new murine MYCN-amplified neuroblastoma cell line
Authors: Alexander Stermann, Nicole Huebener, Stefan Fest, Anja Wohler, Bianca Baykan, Gerhard Geadicke, Holger Lode
Journal: Cancer Research (2008)

1020  Neuroblastoma is the most common solid extra cranial tumor in childhood accounting for 8-10% of all childhood cancers. High-level expression of MYCN plays an important role in maintaining the malignant phenotype of neuroblastoma and is the most significant predictor of rapid tumor progression and poor prognosis overall. The MYCN oncogene is amplified in more than 40% of patients with advanced disease. Especially for these patients the development of new adjuvant therapeutic strategies is desperately needed.  Recent studies suggested that MYCN is a suitable target for tumor immunotherapy, but up to now, a syngeneic MYCN-amplified neuroblastoma mouse model is not available to examine new therapeutic strategies in vivo.  Here, we report for the first time the establishment of a MYCN-amplified murine neuroblastoma cell line syngeneic to A/J mice. For this purpose we used NXS2 cells. NXS2 is a murine neuroblastoma cell line derived from A/J mice with one copy of the MYCN oncogene characterized by low MYCN protein expression. We stably integrated the MYCN cDNA into NXS2 cells by using a lentiviral system based on the vectors pMD2G, pMDLg/pRRE, pRSV Rev and pPRIE7. Stable transduction was verified by real-time PCR and Western-Blot, revealing significantly higher expression levels of MYCN compared the human MYCN-amplified cell line Kelly, which contains about 120 copies of the MYCN gene. Additionally, the expression of the new NXS2-MYCN cells is about 25 fold higher than in the wildtype NXS2 cells. Characterization of the murine MYCN-amplified cells in vitro and in vivo will be reported.  In summary, we report the development of a new murine MYCN-amplified neuroblastoma cell line providing for an important new syngeneic model for the in vivo evaluation of new therapeutic strategies for this highly aggressive type of neuroblastoma.
Cholera Toxin Subunit B Enabled Multifunctional Glioma‐Targeted Drug Delivery
Authors: Juan Guan, Zui Zhang, Xuefeng Hu, Yang Yang, Zhilan Chai, Xiaoqin Liu, Jican Liu, Bo Gao, Weiyue Lu, Jun Qian, Changyou Zhan
Journal: Advanced Healthcare Materials (2017)

Abstract Glioma is among the most formidable brain cancers due to location in the brain. Cholera toxin subunit B (CTB) is investigated to facilitate multifunctional glioma‐targeted drug delivery by targeting the glycosphingolipid GM1 expressed in the blood–brain barrier (BBB), neovasulature, and glioma cells. When modified on the surface of poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles (CTB‐NPs), CTB fully retains its bioactivity after 24 h incubation in the fresh mouse plasma. The formed protein corona (PC) of CTB‐NP and plain PLGA nanoparticles (NP) after incubation in plasma is analyzed using liquid chromatography tandem massspectrometry (nano‐LC‐MS/MS). CTB modification does not alter the protein components of the formed PC, macrophage phagocytosis, or pharmacokinetic profiles. CTB‐NP can efficiently penetrate the in vitro BBB model and target glioma cells and human umbilical vascular endothelial cells. Paclitaxel is loaded in NP (NP/PTX) and CTB‐NP (CTB‐NP/PTX), and their antiglioma effects are assessed in nude mice bearing intracranial glioma. CTB‐NP/PTX can efficiently induce apoptosis of intracranial glioma cells and ablate neovasulature in vivo, resulting in significant prolongation of survival of nude mice bearing intracranial glioma (34 d) in comparison to those treated with NP/PTX (29 d), Taxol (24 d), and saline (21 d). The present study suggests a potential multifunctional glioma‐targeted drug delivery system enabled by cholera toxin subunit B.
Neuroendocrine tumors of the head and neck: SEER analysis of survival and incidence.
Authors: Saad A. Khan, Hong Zhu, Maria Bacalao
Journal: Journal of Clinical Oncology (2015)

e17051 Background: Head and neck neuroendocrine tumors are rare, with limited information regarding frequency, prognosis and significance of site. Methods: A case listing session of SEER 18 (1973-2011) was used to gather staging and outcome information on patients with neuroendocrine tumors in the head/neck, identifying 1,346 cases. We used SEER*Stat 8.1.15, Microsoft Excel and STATA software for analysis. Kaplan Meier method and log-rank test were used to determine survival by site and metastatic status. Results: 1,346 patients with head and neck neuroendocrine tumors were identified. Of these 549 had small cell carcinoma, 473 had neuroendocrine tumor NOS, 271 had large cell carcinoma and 53 had carcinoid tumor. Incidence by site was: 29% salivary glands, 25% larynx/hypopharynx, 18% nasopharynx, 16% paranasal sinuses, and 13% mouth/oropharynx. 1,288 patients had cancer survival time/vital status information. Estimated median survival for all patients was 25 months. 530 patients had metastatic status recorded as M1 or M0; 81% were M0 and 19% were M1. 716 patients had unknown metastatic status or it could not be determined. T and N stages varied depending on metastatic status (refer to table). Median survival was significantly prolonged in M0-45 months (range 1-94) vs. M1-9 months (range 1-60) (p=<0.001). With Kaplan-Meier method and log-rank test there was a statistically significant difference in overall survival between sites (p=<0.001). It was longest for nasopharynx (n=232) 37 months (range 1-270) and sinuses (n=202) 28 months (range 1-283). Salivary gland (n=377) survival was 28 months (range 1-339) but was associated with many later events. Survival was shortest for oropharynx (n=160) 16 months (range 1-209) and hypopharynx (n=317) 18 months (range 1-270). Conclusions: Neuroendocrine head and neck tumor survival statistically significantly varied by site and metastatic status, with tumors in the oropharynx and hypopharynx having poorer prognosis compared to nasopharynx and sinuses. In this population metastases were uncommon but associated with a much shorter survival. Percentage of T and N stages as by metastatic status. M0 M1 0 1 2 3 4 X 0 1 2 3 4 X T 1 23 26 19 21 10 0 13 19 24 29 15 N 44 19 31 4 2 19 30 36 5 10
Long‐term follow‐up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non‐Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)
Authors: Thomas E. Witzig, Patrick B. Johnston, Betsy R. LaPlant, Paul J. Kurtin, Levi D. Pederson, Dennis F. Moore Jr, Nassim H. Nabbout, Daniel A. Nikcevich, Kendrith M. Rowland, Axel Grothey
Journal: American Journal of Hematology (2017)

Abstract Patients with relapsed aggressive non‐Hodgkin lymphoma (NHL) are often treated with platinum‐based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m 2 IV weekly x 4 doses (cycle 1 only); dexamethasone 40 mg PO/IV d2 – 5; oxaliplatin 130 mg/m 2 IV day 2; cytarabine 2000 mg/m 2 IV × two doses on days 2 to 3; and pegfilgrastim 6 mg SC on day 4. Forty‐five eligible patients were accrued between 2006 and 2008. Patient characteristics were a median age of 69 years; 96% had received prior rituximab; 53% were within one year of diagnosis. The median number of cycles received was 2 (range, 1‐6). Forty‐four % received ROAD as an outpatient. The overall response rate was 71% with 27% (12/45) CR and 44% (20/45) PR. Forty‐four % (20/45) of all patients and 69% (18/26) of patients whom responded after 2 cycles proceeded to transplant. Median overall survival was 26 mos (95% CI: 7.3 mos—not reached) and median progression‐free survival was 11 mos (95% CI: 6—104 mos). There was no grade 3/4 nephrotoxicity; the rate of grade 3/4 neuropathy was 4%. Forty‐two percent of all patients and 69% of patients transplanted remain alive at 5 years. ROAD represents an acceptable salvage therapeutic option for patients with relapsed aggressive NHL.
PPAR gamma treatment promotes lipid accumulation, decreases cyclin D1, and reduces in vivo growth of adenoid cystic cancer
Authors: Beverly Wuertz, Frank Ondrey
Journal: Cancer Research (2008)

2295  Adenoid cystic carcinoma is an epithelially derived salivary gland malignancy which is most often fatal over a decade or greater because of a phenotype characterized by neurotropic growth and blood borne metastasis. Because of its slow growth and radiochemoresistant phenotype, differentiation therapy may be a very good option. PPAR gamma activators are a class of drugs that differentiate certain types of malignancies and are being investigated currently in clinical chemoprevention. Recent studies have implicated upregulation of cyclin D1 as a characteristic of these tumor cells in tissue specimens. In the present study we investigated effects of PPAR gamma activators on the growth of human adenoid cystic ACC-3 cells in nude mice as well as possible adipose phenotype transdifferentiation events in vitro. We performed RT-PCR for fat differentiation markers including FABP 4, Adipsin, and PPAR Gamma and quantitated Oil red O staining. After one week of treatment with 10 uM pioglitazone, rosiglitazone, or ciglitazone, Oil red O levels were increased 6-90 fold in treated cells over controls (P
Hemophilia Liver Transplant Observational Study (HOTS)
Authors: Margaret V. Ragni, Abhinav Humar, Peter G. Stock, Emily A. Blumberg, Bijan Eghtesad, John Fung, Valentina Stosor, Nicholas NIssen, Michael T. Wong, Kenneth E. Sherman, Donald Stablein, Burc Barin
Journal: Blood (2016)
YAP依存性メカノトランスダクションは天然様基板トポグラフィーの増殖と移動に必要である【Powered by NICT】
Authors: Mascharak Shamik, L Benitez Patrick, C Proctor Amy, M Madl Christopher, H Hu Kenneth, E Dewi Ruby, J Butte Manish, C Heilshorn Sarah
Journal: Biomaterials (2017)
抗菌ペプチドのデリバリーを共役支援金ナノ粒子DNAアプタマーは細胞内Salmonella enterica serovar Typhimuriumを効果的に除去できる【Powered by NICT】
Authors: Yeom Ji-Hyun, Lee Boeun, Kim Daeyoung, Lee Jong-kook, Kim Suk, Bae Jeehyeon, Park Yoonkyung, Lee Kangseok
Journal: Biomaterials (2016)
アルツハイマー病と加齢における脳萎縮【Powered by NICT】
Authors: Pini Lorenzo, Pievani Michela, Bocchetta Martina, Altomare Daniele, Bosco Paolo, Cavedo Enrica, Galluzzi Samantha, Marizzoni Moira, B Frisoni Giovanni
Journal: Ageing Research Reviews (2016)
Empyema necessitans and a persistent air leak associated with rupture of an anaerobic lung abscess due to bacteroides
Authors: Varun Sharma, Kevin G Blyth
Journal: Thorax (2017)

Here we report an unusual case of ruptured lung abscess, complicated by both a persistent air leak and empyema necessitans. This combination of problems, in a patient with significant co-morbidities presented major diagnostic difficulties and challenging pleural intervention issues . The case based discussion presented also highlights a number of important learning points that can be generalised to the assessment and management of patients with severe pleuro-pulmonary infections, including the minority associated with an acute air-leak.

Varun Sharma (VS): A morbidly obese (120 kg, body mass index 49) 43-year-old female presented to the Queen Elizabeth University Hospital Glasgow, obtunded and in acute respiratory distress. She had been bed or chairbound for 2 years due to chronic pain, primarily related to severe hidradenitis suppurativa (HS). Other past medical history included poorly controlled Insulin-dependent type 2 diabetes mellitus (glycated haemoglobin (HbA1c) level 107 mmol/mol on admission), asthma and non-alcoholic fatty liver disease. She reported a cough productive of large volumes of purulent, foul-smelling sputum and severe pain, particularly localised to the axillae and lateral chest walls. The patient was tachycardic (147 bpm), tachypnoeic and hypoxic. Oxygen saturations were recorded at 85% on air. Examination revealed accessory muscle use, reduced air entry, dullness to percussion and bronchial breathing at the right lung base. The patient did not tolerate a full skin examination due to pain, and reported multiple drug allergies, including suxamethonium and metronidazole, but no penicillin allergy. Treatment for probable community-acquired pneumonia was initiated (intravenous amoxicillin and oral clarithromycin) pending chest radiography. Initial laboratory investigations revealed a C reactive protein level over 300 mg/L and marked hypoalbuminaemia (14 g/L). Over the next few hours, the patient reported facial swelling. On repeat clinical assessment, no stridor or airway compromise was noted. Antibiotic allergy was suspected, and intravenous hydrocortisone and chlorphenamine were administered. However, her facial swelling worsened and a chest radiograph, acquisition of which has been delayed, revealed significant …
Risk Factors for Adverse Events in Emergency Department Procedural Sedation for Children
Authors: Maala Bhatt, David W. Johnson, Jason Chan, Monica Taljaard, Nick Barrowman, Ken J. Farion, Samina Ali, Suzanne Beno, Andrew Dixon, C. Michelle McTimoney, Alexander Sasha Dubrovsky, Nadia Sourial, Mark G. Roback
Journal: JAMA Pediatrics (2017)

Procedural sedation for children undergoing painful procedures is standard practice in emergency departments worldwide. Previous studies of emergency department sedation are limited by their single-center design and are underpowered to identify risk factors for serious adverse events (SAEs), thereby limiting their influence on sedation practice and patient outcomes.To examine the incidence and risk factors associated with sedation-related SAEs.This prospective, multicenter, observational cohort study was conducted in 6 pediatric emergency departments in Canada between July 10, 2010, and February 28, 2015. Children 18 years or younger who received sedation for a painful emergency department procedure were enrolled in the study. Of the 9657 patients eligible for inclusion, 6760 (70.0%) were enrolled and 6295 (65.1%) were included in the final analysis.The primary risk factor was receipt of sedation medication. The secondary risk factors were demographic characteristics, preprocedural medications and fasting status, current or underlying health risks, and procedure type.Four outcomes were examined: SAEs, significant interventions performed in response to an adverse event, oxygen desaturation, and vomiting.Of the 6295 children included in this study, 4190 (66.6%) were male and the mean (SD) age was 8.0 (4.6) years. Adverse events occurred in 736 patients (11.7%; 95% CI, 6.4%-16.9%). Oxygen desaturation (353 patients [5.6%]) and vomiting (328 [5.2%]) were the most common of these adverse events. There were 69 SAEs (1.1%; 95% CI, 0.5%-1.7%), and 86 patients (1.4%; 95% CI, 0.7%-2.1%) had a significant intervention. Use of ketamine hydrochloride alone resulted in the lowest incidence of SAEs (17 [0.4%]) and significant interventions (37 [0.9%]). The incidence of adverse sedation outcomes varied significantly with the type of sedation medication. Compared with ketamine alone, propofol alone (3.7%; odds ratio [OR], 5.6; 95% CI, 2.3-13.1) and the combinations of ketamine and fentanyl citrate (3.2%; OR, 6.5; 95% CI, 2.5-15.2) and ketamine and propofol (2.1%; OR, 4.4; 95% CI, 2.3-8.7) had the highest incidence of SAEs. The combinations of ketamine and fentanyl (4.1%; OR, 4.0; 95% CI, 1.8-8.1) and ketamine and propofol (2.5%; OR, 2.2; 95% CI, 1.2-3.8) had the highest incidence of significant interventions.The incidence of adverse sedation outcomes varied significantly with type of sedation medication. Use of ketamine only was associated with the best outcomes, resulting in significantly fewer SAEs and interventions than ketamine combined with propofol or fentanyl.
Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish
Authors: J-W Lu, M-S Hsieh, H-A Hou, C-Y Chen, H-F Tien, L-I Lin
Journal: Blood Cancer Journal (2017)

The SOX4 transcription factor is a key regulator of embryonic development, cell-fate decision, cellular differentiation and oncogenesis. Abnormal expression of SOX4 is related to malignant tumor transformation and cancer metastasis. However, no reports are available regarding the clinical significance of SOX4 in acute myeloid leukemia (AML) and the role of SOX4 in leukemogenesis. In the current study, we found that AML patients with low bone marrow (BM) SOX4 expression had higher remission rates and longer overall survival than those with high SOX4 expression, regardless of age, white blood cell count at diagnosis, karyotype profile and NPM1/FLT3-ITD status. To elucidate the role of SOX4 in leukemogenesis, we generated a transgenic zebrafish model that overexpressed human SOX4 in the myeloid lineage Tg(spi1-SOX4-EGFP). These transgenic zebrafish showed, at 5 months of age, increased myelopoiesis with dedifferentiation in kidney marrow. At 9 months of age, their kidney structure was significantly effaced and distorted by increased infiltration of myeloid progenitor cells. These results suggest that SOX4 is not only an independent prognostic factor of AML, but also an important molecular factor in leukemogenesis.
Development of Novel Human Anti-HLA-Monoclonal Antibodies for Clinical Applications Using Peripheral Blood B Cells Derived from Anti-HLA Antibody-Positive Donors
Authors: Hiroyuki Takamatsu, Yoshitaka Zaimoku, Tatsuhiko Ozawa, Shintaro Kawai, Hidenori Tanaka, Hiroyuki Kishi, Atsushi Muraguchi, Shinji Nakao
Journal: Blood (2016)
Inotropic myocardial reserve deficiency is the predominant feature of exercise haemodynamics in cardiac amyloidosis
Authors: Tor Skibsted Clemmensen, Henning Mølgaard, Jens Sörensen, Hans Eiskjaer, Niels Frost Andersen, Søren Mellemkjaer, Mads Jønsson Andersen, Lars Poulsen Tolbod, Hendrik J. Harms, Steen Hvitfeldt Poulsen
Journal: European Journal of Heart Failure (2017)
Diagnostic Errors and Diagnostic Calibration
Authors: Adam S. Cifu
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal